Page 79 - Update on Management of Renal Cell Carcinoma

Ongoing Phase 3 Studies with Immuno-oncology

Therapies in Advanced RCC

Primary Projected primary
Study name Interventions N
endpoint(s) completion date

Pembrolizumab +
KEYNOTE-679 1 epacadostat vs. sunitinib or 129 ORR Aug. 2018
(NCT03631784)
pazopanib

Checkmate-9ER 2 Nivolumab + cabozantinib
(NCT03141177) 630 PFS Sept. 2019
vs. sunitinib

Lenvatinib + everolimus vs.
CLEAR 3 lenvatinib +

(NCT02811861) 1,050 PFS Apr. 2020
pembrolizumab vs.
sunitinib

CA045002 4 Nivolumab + NKTR-214 vs.

(NCT03729245) 600 ORR, OS Dec. 2021
sunitinib or cabozantinib

ORR: objective response rate; OS: overall survival; PFS: progression-free survival; RCC: renal cell carcinoma

1. https://clinicaltrials.gov/ct2/show/NCT03631784. Accessed March 3, 2019.
2. https://clinicaltrials.gov/ct2/show/NCT03141177. Accessed March 3, 2019.
3. https://clinicaltrials.gov/ct2/show/NCT02811861. Accessed March 3, 2019.
79 4. https://clinicaltrials.gov/ct2/show/NCT03729245. Accessed March 3, 2019.